Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Gastroenterology

• Publication date

  2017-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.gastro.2017.08.039PMID 28859855PMCID PMC5705280
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PHLPPing through history: a decade in the life of PHLPP phosphatases.

  2016cited by this paper
• Staphylococcus aureus Coordinates Leukocidin Expression and Pathogenesis by Sensing Metabolic Fluxes via RpiRc

  2016cited by this paper
• mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2

  2016cited by this paper
• Effects of multiple ascending doses of the glucagon receptor antagonist PF‐06291874 in patients with type 2 diabetes mellitus

  2016cited by this paper
• The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.

  2016cited by this paper
• Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?

  2016cited by this paper
• Ndel1 suppresses ciliogenesis in proliferating cells by regulating the trichoplein–Aurora A pathway

  2016cited by this paper
• The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

  2016cited by this paper
• Systems proteomics of liver mitochondria function

  2016cited by this paper
• Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.

  2016cited by this paper
• Free-electron creation at the 60° twin boundary in Bi2Te3

  2016cited by this paper
• Structural Insights into KCTD Protein Assembly and Cullin3 Recognition.

  2016cited by this paper
• Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes

  2015cited by this paper
• The new biology of diabetes

  2015cited by this paper
• Ubiquitin-proteasome system controls ciliogenesis at the initial step of axoneme extension

  2014cited by this paper
• Turning off AKT: PHLPP as a drug target.

  2014cited by this paper
• Integrated Control Of Hepatic Lipogenesis Vs. Glucose Production Requires FoxO Transcription Factors

  2014cited by this paper
• The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes

  2014cited by this paper
• Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation

  2014cited by this paper
• DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery.

  2013cited by this paper
• Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability

  2013cited by this paper
• Byonic: Advanced Peptide and Protein Identification Software

  2012cited by this paper
• Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.

  2011cited by this paper
• Insulin signaling to hepatic lipid metabolism in health and disease

  2011cited by this paper
• Genetic control of de novo lipogenesis: role in diet-induced obesity

  2010cited by this paper
• Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis

  2010cited by this paper
• Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

  2010cited by this paper
• Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.

  2009cited by this paper
• Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis.

  2008cited by this paper
• The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.

  2007cited by this paper
• Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia

  2006cited by this paper
• Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism.

  2006cited by this paper
• Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice

  2006cited by this paper
• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

  2005cited by this paper
• PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

  2005cited by this paper
• Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

  2004cited by this paper
• Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction

  2003cited by this paper
• Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction.

  2003cited by this paper
• Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

  2003cited by this paper
• SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

  2002cited by this paper
• Mechanisms of nutritional and hormonal regulation of lipogenesis

  2001cited by this paper
• Insulin signalling and the regulation of glucose and lipid metabolism

  2001cited by this paper
• Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice.

  2000cited by this paper
• Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans.

  1998cited by this paper
• A role for the serine/threonine kinase, Akt, in insulin-stimulated glucose uptake.

  1997cited by this paper
• Glucagon and its Family Revisited

  1995cited by this paper
• Expression cloning and signaling properties of the rat glucagon receptor.

  1993cited by this paper
• Contribution to Postprandial Hyperglycemia and Effect on Initial Splanchnic Glucose Clearance of Hepatic Glucose Cycling in Glucose-Intolerant or NIDDM Patients

  1991cited by this paper
• Cyclic AMP second messenger systems.

  1991cited by this paper
• A simple method for the isolation and purification of total lipides from animal tissues.

  1957cited by this paper
• Serveur Académique Lausannois SERVAL serval.unil.ch

  year unknowncited by this paper

• The Cul3 ubiquitin ligase engages Insomniac as an adaptor to impact sleep and synaptic homeostasis

  2025cites this paper
• Rearrangement of the liver ubiquitome and NEDDylome in metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Hypomethylation‐Enhanced F‐Box Protein 32 Promotes Hepatocellular Carcinogenesis via Ubiquitin‐Mediated PHLPP2 Degradation

  2025cites this paper
• Hepatocyte KCTD17-mediated SERPINA3 inhibition determines liver fibrosis in metabolic dysfunction-associated steatohepatitis

  2025cites this paper
• Recent advances in PHLPP1 and PHLPP2 research: an update in the heart

  2025cites this paper
• PHLPP: a Janus-faced regulator in oncogenesis.

  2025cites this paper
• Overview of insulin: more than a hormone for controlling glucose level

  2025cites this paper
• Ginsenoside-Re-rich ethanol extract of Panax ginseng berry enhances healthspan extension via mitostasis and NAD metabolism

  2024cites this paper
• Bioinformatics-Based Construction of Immune-Related microRNA and mRNA Prognostic Models for Hepatocellular Carcinoma

  2024cites this paper
• Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease.

  2024cites this paper
• Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”

  2024cites this paper
• KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression

  2024cites this paper
• Diabetes mellitus-Progress and opportunities in the evolving epidemic.

  2024cites this paper
• LncRNA CCAT1 knockdown suppresses tongue squamous cell carcinoma progression by inhibiting the ubiquitination of PHLPP2

  2024influential citation
• Changes in Cells Associated with Insulin Resistance

  2024cites this paper
• Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases

  2023cites this paper
• Kctd17-mediated Chop degradation promotes adipogenic differentiation.

  2023cites this paper
• miR-27b targets MAIP1 to mediate lipid accumulation in cultured human and mouse hepatic cells

  2023cites this paper
• PHLPP isoforms differentially regulate Akt isoforms and AS160 affecting neuronal insulin signaling and insulin resistance via Scribble

  2022cites this paper
• Ubiquitin-like posttranslational modifications in NAFLD progression and treatment

  2022cites this paper
• Mitoribosome insufficiency in β cells is associated with type 2 diabetes-like islet failure

  2022cites this paper
• PHLPPs: emerging players in metabolic disorders.

  2022cites this paper
• Machine learning-featured Secretogranin V is a circulating diagnostic biomarker for pancreatic adenocarcinomas associated with adipopenia

  2022cites this paper
• Hepatocyte Kctd17 inhibition ameliorates glucose intolerance and hepatic steatosis caused by obesity-induced Chrebp stabilization.

  2022cites this paper
• Co-Expression Network Revealed The Potential Regulatory Mechanism of lncRNAs In Relapse Hepatocellular Carcinoma.

  2021cites this paper
• Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver

  2021cites this paper
• Insulin Resistance: From Mechanisms to Therapeutic Strategies

  2021influential citation
• A Co-Expression Network Reveals the Potential Regulatory Mechanism of lncRNAs in Relapsed Hepatocellular Carcinoma

  2021cites this paper
• Colonic Epithelial PHLPP2 Deficiency Promotes Colonic Epithelial Pyroptosis by Activating the NF-κB Signaling Pathway

  2021cites this paper
• Emerging roles of PHLPP phosphatases in metabolism

  2021cites this paper
• Oncogenic role of MIR516A in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy

  2020cites this paper
• CMAR_A_256670 11341..11350

  2020cites this paper
• miR-141 Promotes Colon Cancer Cell Proliferation by Targeted PHLPP2 Expression Inhibitionn

  2020cites this paper
• Liver-selective γ-secretase inhibition ameliorates diet-induced hepatic steatosis, dyslipidemia and atherosclerosis.

  2020cites this paper
• Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)

  2020cites this paper
• Mechanisms of Fibrosis Development in NASH.

  2020cites this paper
• PHLPP2 as a novel metastatic and prognostic biomarker in non‐small cell lung cancer patients

  2019cites this paper
• Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine

  2019cites this paper
• Quantitative Phosphoproteomics Reveals System-Wide Phosphorylation Network Altered by Spry in Mouse Mammary Stromal Fibroblasts

  2019influential citation
• γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor.

  2018influential citation